✦ LIBER ✦

Phase II study of oral etoposide for patients with advanced breast cancer

✍ Scribed by Daniel M. Atienza; Charles L. Vogel; Bruce Trock; Sandra M. Swain

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 562 KB
Volume: 76
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19951215)76:12<2485::aid-cncr2820761212>3.0.co;2-j

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study with etoposide in previou

Phase II study with etoposide in previously untreated advanced breast cancer

✍ Hans-Erik Wander; Winrich Rauschning; Dirk Meyer; Wolfgang Achterrath; Gerd-Arno 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 281 KB

Phase I–II study of high-dose etoposide

Phase I–II study of high-dose etoposide in patients with refractory breast cancer

✍ Giuseppe Fraschini; Frankie A. Holmes; Laura Esparza; Richard L. Theriault; Aman 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 162 KB

A phase I study of chronic daily dosing

A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer

✍ Masahiro Fukuoka; Noriyuki Masuda; Shunichi Negoro; Minoru Takada; Shinzoh Kudoh 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB 👁 2 views

Second-line chemotherapy with long-term

Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer

✍ M. Bontenbal; A. S. Th. Planting; J. Verweij; R. Wit; W. H. J. Kruit; G. Stoter; 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 377 KB

A phase II study of oral idarubicin (4-d

A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer

✍ Nicholas S. A. Stuart; Michael H. Cullen; Terrence J. Priestman; George R. P. Bl 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 352 KB

Idarubicin (4-demethoxydaunorubicin: DMDNR) is an orally active analogue of daunorubicin that has shown promising activity in animal and early clinical studies. We gave idarubicin in a phase II study to patients with advanced breast cancer unresponsive to hormonal manipulation and in some cases to s

Phase II study of a modified combination

Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer

✍ Içli, Fikri; Karaoguz, Handan; Akbulut, Hakan; Dinçol, Dilek; Demirkazik, Ahmet; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB 👁 2 views

## Background: Based on the promising results of eap (etoposide, doxorubicin, and cisplatin) combination, a phase ii study of modified eap combination was performed in patients with advanced gastric cancer to evaluate the response, toxicity, and survival. ## Method: Fifty-two consecutive patients